Research & Development

A fundamental transformation is underway in the landscape of cancer research funding, signaling a deliberate pivot from broad, generalized support to a highly strategic, multi-pronged investment in the future of oncology. This sophisticated approach is built upon a clear consensus that progress

As a biopharma expert deeply invested in the intersection of technology and healthcare delivery, I’ve spent my career focused on innovation in research and development. My latest work, however, has shifted focus to a more fundamental problem: the stubborn gaps in who gets to benefit from modern

A powerful convergence of artificial intelligence, novel therapeutic platforms, and fierce market competition is fundamentally reshaping the biopharmaceutical industry, accelerating the pace of discovery from the laboratory to the clinic. This period of rapid advancement is not defined by a single

The delicate balance of pharmaceutical innovation often hinges on a single set of clinical data, and for the Belgian biotech firm Galapagos, the recent trial results for its experimental drug GLPG3667 have created a narrative of both triumph and tribulation. This TYK2 inhibitor, designed to quell

The cutting edge of cancer treatment often involves a delicate and high-stakes balance between revolutionary efficacy and severe, sometimes fatal, side effects. This reality has been starkly highlighted as a pivotal late-stage clinical trial for a promising new cancer therapy, ifinatamab deruxtecan

In an industry where the path from laboratory concept to patient bedside is often decades long and costs billions, the traditional, siloed approach to research and development is proving increasingly insufficient for tackling today's complex medical challenges. A new paradigm of "open innovation"